SNPMiner Trials (Home Page)
Report for Clinical Trial NCT03383224
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
Angina and Genotype-Guided Smoking Cessation In PRISM-GENOMICS
It has previously been shown that patients with coronary artery disease may have a harder time quitting smoking if they have a specific genetic profile and that these individuals have a better chance at quitting if they receive nicotine replacement therapy. The investigators hypothesize that determining which individuals with coronary artery disease should receive nicotine replacement therapy based on their genotype may improve the number of individuals who are able to quit smoking.This study randomizes treatment to that determined by the patient's genotype compared to standard, non-genotype-guided, treatment.
NCT03383224 Coronary Artery Disease Smoking Cessation MeSH:Coronary Artery Disease Myocardial Ischemia Coronary Disease
HPO:Coronary artery atherosclerosis Myocardial infarction
3 Interventions
Name: genotype-guided therapy
Name: Nicotine patch
Name: Smoking cessation counseling
Primary Outcomes
Description: Number of participants no longer smoking as assessed by telephone-administered questionnaire
Measure: Smoking Cessation Time: 1 month after enrollmentSecondary Outcomes
Description: Number of participants no longer smoking as assessed by telephone-administered questionnaire
Measure: Smoking Cessation Time: 6 months after enrollmentDescription: Number of participants no longer smoking as assessed by telephone-administered questionnaire
Measure: Smoking Cessation Time: 12 months after enrollmentPurpose: Other
Allocation: Randomized
Parallel Assignment
There is one SNP
SNPs
1 rs16969968
intubated) - Incarcerated - Complications of myocardial infarction (such as shock, hemodynamic instability, life- threatening infection, etc) - Women of child-bearing age with positive pregnancy test or who is breast feeding Coronary Artery Disease Smoking Cessation Coronary Artery Disease Myocardial Ischemia Coronary Disease In this study, the investigators propose to show the feasibility of incorporating genotype-guided therapy into post-MI smoking cessation therapy and/or smoking cessation therapy in patients with coronary artery disease (CAD) using the CHRNA5 rs16969968 variant as the pilot case.
The investigators propose to genotype ½ of PRISM-GENOMICs patients who are active smokers within 48 hours of admission and to guide their smoking cessation therapy based on CHRNA5 rs16969968 genotype (A allele carriers will be given pharmacologic therapy and GG homozygotes will be given counseling).